PPARD and obesity due to melanocortin 4 receptor deficiency: In studies conducted in OLETF rats, a model of T2DM with obesity, the synthetic PPARD agonist GW0742 attenuated hepatic fat accumulation and improved insulin signaling [21], validating PPARD as a potential mediator of metabolic disease and a promising target for prevention and/or therapy.